Quantum-Si incorporated
NASDAQ:QSIBiotechnology
+$0.05 today
- Market cap
- $213.79M
- Beta
- 3.17
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.48
Volume 10.47M
Average 5.64M
QSI Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Quantum-Si incorporatedNASDAQ: QSI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $1.23M rose 33.6% year over year, ahead of the +6.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.
Context
- Depreciation & amortization amounted to 182.8% of revenue in FY2025, up 32.4 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +33.6% holds above the trailing-twelve-month pace of +6.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 4.45M USD
- Year-over-year change
- -3.2%
- 4-year CAGR
- +43.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.45M | -3.2% |
| FY2024 | 2024-12-31 | 4.6M | +10.7% |
| FY2023 | 2023-12-31 | 4.16M | +60.8% |
| FY2022 | 2022-12-31 | 2.58M | +148.2% |
| FY2021 | 2021-12-31 | 1.04M | — |
Depreciation & Amortization vs competitors
How QSI compares with its peers on the latest reported figures
- QSI's LTM Mar 2026 depreciation & amortization of $4.76M is the 3rd largest of the 11 companies compared; the peer median is $1.48M.
- Its year-over-year change of +6.9% is the 4th highest of 10, against a peer median of +0.4%.
- Depreciation & amortization amounts to 257.1% of revenue for QSI, versus a peer median of 13.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.18M | +16.3% | +9.8% | 13.2% | |
| LTM Mar 2026 | $10.18M | +0.4% | +20.7% | — | |
| LTM Mar 2026 | $4.76M | +6.9% | +19.9% | 257.1% | |
| LTM Mar 2026 | $3.14M | +14181.8% | -37.6% | — | |
| LTM Mar 2026 | $2.18M | -186.0% | — | — | |
| LTM Mar 2026 | $2.17M | +0.9% | +0.9% | — | |
| LTM Mar 2026 | $1.84M | -31.3% | -31.1% | 2.3% | |
| LTM Mar 2026 | $1.11M | -7.9% | -1.4% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K | +79.6% | +28.8% | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $106K | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding QSI) | $1.48M | +0.4% | +0.9% | 13.2% | |
Competitors are the stored peer set for QSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (94.99M) | (132.44M) | (95.96M) | (101.01M) | (101.34M) |
| Depreciation & Amortization | 1.04M | 2.58M | 4.16M | 4.6M | 4.45M |
| Deferred Income Tax | 714K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.92M | 11.21M | 8.52M | 8.89M | 10.77M |
| Change in Working Capital | 1.47M | 3.05M | (3.2M) | 4.64M | (4.58M) |
| Accounts Receivables | 0 | 0 | (368K) | (1.09M) | 626K |
| Inventory | 0 | 0 | 286K | 4.34M | (2.01M) |
| Accounts Payables | 709K | 721K | (1.22M) | 390K | (338K) |
| Other Working Capital | 758K | 2.33M | (1.89M) | 1M | (2.86M) |
| Other Non-Cash Items | 36K | 25.04M | (7.55M) | (4.92M) | (4.03M) |
| Operating Cash Flow | (66.81M) | (90.56M) | (94.04M) | (87.8M) | (94.72M) |
| Capital Expenditures | (5.76M) | (10.74M) | (5.27M) | (4.58M) | (2.52M) |
| Acquisitions (Net) | (4.63M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (440.54M) | (834K) | (123.81M) | (369.43M) | (404.58M) |
| Sales of Investments | 445.17M | 148.76M | 272.51M | 341.4M | 378.78M |
| Other Investing Activities | (445.17M) | 0 | (763K) | (59K) | 0 |
| Investing Cash Flow | (450.94M) | 137.19M | 143.43M | (32.68M) | (28.32M) |
| Debt Repayment | (1.78M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 512.79M | 2.76M | 0 | 34.79M | 95.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.61M | (848K) | 149K | 1.09M | 1K |
| Financing Cash Flow | 516.63M | 1.91M | 149K | 35.88M | 95.42M |
| Effect of Forex Changes | 0 | 0 | 0 | (25K) | 12K |
| Net Change in Cash | (1.13M) | 48.53M | 49.54M | (84.62M) | (27.6M) |
| Free Cash Flow | (72.58M) | (101.3M) | (99.31M) | (92.38M) | (97.23M) |
Quantum-Si incorporated
NASDAQ:QSI
Intrinsic Alpha fair value
Locked
Current Price
$1.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.